自然蛋白转化酶亚素/素9型抑制剂:一篇评论
Sonia Singh1, Himanshu Sharma2, Raghavan Ramankutty3
1Institute of Pharmaceutical Research, GLA University, Mathura, U.P, 281406, India.
Combinatorial chemistry & high throughput screening
|June 27, 2023
概括
目前正在探索天然存在的蛋白转化酶抑制剂亚素/素9型 (PCSK9) 抑制剂,以开发新的口服疗法. 这些化合物可以帮助更多的患者达到他们的LDL胆固醇目标,特别是当与他类药物一起使用时.
科学领域:
- 生物化学 生物化学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 蛋白转化酶亚素/素9型 (PCSK9) 在调节低密度脂蛋白胆固醇 (LDL-C) 水平方面发挥着关键作用,影响心血管事件.
- 目前的PCSK9向疗法主要是可注射的,这限制了患者的坚持和可访问性.
- 开发口服抗PCSK9药物是心血管疾病管理中的重大未满足需求.
研究的目的:
- 审查具有PCSK9抑制活性的天然化合物和提取物.
- 确定开发新型口服PCSK9向治疗的潜在起点.
- 探索改善患者实现LDL胆固醇目标的策略,特别是与他类药物一起使用时.
主要方法:
- 关于天然PCSK9抑制剂的科学研究的文献综述.
- 分析报告的自然化合物抑制PCSK9的机制.
- 关于这些天然抑制剂的疗效和潜力的研究结果的摘要.
主要成果:
- 一些天然成分和提取物显示出抑制PCSK9的活性.
- 这些天然抑制剂为开发口服可用的抗PCSK9剂提供了有希望的途径.
- 与他类药物联合治疗的潜力,以增强LDL-C降低.
结论:
- 识别和表征天然PCSK9抑制剂对于推进口服心血管治疗至关重要.
- 自然化合物可以作为开发有效,口服的LDL-C降低剂的支架.
- 这项研究强调了天然产品的潜力,可以补充现有的治疗方法,如改善心血管健康的他类药物.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Glucagon-like Receptor Agonists
366
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
366
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Protein-protein Interfaces
12.6K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.6K
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
Enzyme Inhibition
78.8K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.8K


